Abstract:Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine. Kinetically, the inhibition occurs competitively, non-competitively or in combination, depending on a carboxylesterase. For example, the calcium channel blocker diltiazem competitively inhibits CES1 but non-competitively inhibits CES2. In addition to inhibited catalysis, several therapeutic agents or disease mediators have been shown to regulate the expression of carboxylesterases. For example, the antiepileptic drug phenobarbital induces both human and rodent carboxylesterases, whereas the antibiotic rifampicin induces human carboxylesterases only. Conversely, the proinflammatory cytokine interleukin-6 (IL-6) suppresses the expression of carboxylesterases across species, but depending on the concentrations of glucose in the culture medium. Transactivation, transrepression and altered mRNA stability contribute to the regulated expression. Several nuclear receptors are established to support the regulation including constitutive androstane receptor, glucocorticoid receptor and pregnane X receptor. In addition, non-ligand transcription factors are also involved in the regulation and exemplified by differentiated embryo chondrocyte-1, nuclear factor (erythroid-derived 2)-like 2 and tumor protein p53. These transcription factors coordinate the regulated expression of carboxylesterases, constituting a regulatory network for the hydrolytic biotransformation.

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice

Adipose tissue-specific ablation of Ces1d causes metabolic dysregulation in mice

Carboxylesterase 1d (Ces1d) does not contribute to cholesteryl ester hydrolysis in the liver

Construction and Characterization of CRISPR/Cas9 Knockout Rat Model of Carboxylesterase 2a Gene

Interfering with Lipid Metabolism Through Targeting CES1 Sensitizes Hepatocellular Carcinoma for Chemotherapy.

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

Construction and Characterization of CRISPR/Cas9 Knockout Rat Model of Carboxylesterase 2a Gene.

Design and Construction of Carboxylesterase 2c Gene Knockout Rats by CRISPR/Cas9

Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and other Transcription Factors

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

A Unique Role of Carboxylesterase 3 (Ces3) in β-Adrenergic Signaling Stimulated Thermogenesis.

Carboxylesterase-2 is a Highly Sensitive Target of the Antiobesity Agent Orlistat with Profound Implications in the Activation of Anticancer Prodrugs.

Hormetic effects of EGC and EGCG on CES1 activity and its rescue from oxidative stress in rat liver S9

Pyrazolone compounds could inhibit CES1 and ameliorates fat accumulation during adipocyte differentiation

Relationship Between Hepatic Phenotype and Changes in Gene Expression in Cytochrome P450 Reductase (POR) Null Mice.

Transcription Factor-Mediated Regulation Of Carboxylesterase Enzymes In Livers Of Mice

Deciphering the species differences in CES1A-mediated hydrolytic metabolism by using a bioluminescence substrate

Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism

17Β-Estradiol Suppresses Carboxylesterases by Activating C-Jun/ap-1 Pathway in Primary Human and Mouse Hepatocytes.